You are here

  • Home
  • Archive
  • Volume 10, Issue 5
  • CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy

Article metrics

Article menu

This article has a correction. Please see:

Clinical/translational cancer immunotherapy
Original research
CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy

 

Online download statistics by month:

Online download statistics by month: May 2022 to July 2025

AbstractFullPdf
May 2022480483247
Jun 2022400409197
Jul 2022246255101
Aug 2022274284135
Sep 202225926271
Oct 2022333340118
Nov 2022252253126
Dec 2022159165103
Jan 202315515782
Feb 2023178183123
Mar 2023212212125
Apr 2023182182109
May 202314614787
Jun 202310310678
Jul 202311711786
Aug 202312112479
Sep 202311711769
Oct 2023166166130
Nov 2023162162101
Dec 2023151153140
Jan 2024152153127
Feb 2024125127101
Mar 2024204208198
Apr 2024174175150
May 2024146148132
Jun 2024161162117
Jul 2024166167135
Aug 2024113113115
Sep 2024121121294
Oct 2024181180143
Nov 2024189190149
Dec 2024238244168
Jan 2025227227144
Feb 2025281281170
Mar 2025227228192
Apr 2025240242177
May 2025212212165
Jun 2025999970
Jul 2025110
Total747075555054